In early-onset severe hemolytic disease of the fetus and newborn (HDFN), transplacental transfer of maternal antierythrocyte IgG alloantibodies causes fetal anemia that leads to the use of high-risk ...
What Is Hemolytic Disease of the Fetus and Newborn? Hemolytic disease of the fetus and newborn (HDFN) is a blood disorder that happens when your blood type doesn't match your baby's blood type during ...
Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Please provide your email address to receive an email when new articles are posted on . Alloimmunization rates were 6.2% for women matched to ABO and Rhesus D and 1.9% for women also matched for c, E ...
Hemolytic disease of the newborn is a type of anemia that begins during pregnancy. It can cause serious illness in a newborn, but it may be diagnosed during prenatal screening and treated to avoid ...
The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN). The Food and Drug ...
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat ...
Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...
LAGOS, Nigeria, Aug. 22, 2025 /PRNewswire/ -- BSV has launched a "Voice of Africa" awareness campaign in African countries to publicise HDFN. What is HDFN and why is it essential to understand it?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback